bpc 157 back pain Peptides for Biomolecular therapies for chronic discogenic

Corona G, et al

Slowing the ramp to the label cadence (2.5 mg start, 2.5 mg steps, four-week holds) dropped that to mid-single digits at every maintenance dose, at no cost to the 12-week result, and the dedicated slow-titration trial reached placebo range. Reaching 15 mg is not the problem

This represents a critical knowledge gap

[R] Though less research has focused on TB500, some preliminary studies indicate it may also modulate certain inflammatory pathways and reduce localized swelling and inflammation, especially in wound healing models

While BPC-157 is a master of angiogenesis and tendon repair, TB 500 Thymosin Beta 4 works through different, complementary mechanisms